Revive Therapeutics and Havn Life Science Enter Into Psychedelic Partnership Agreement

Tim Moore CEO of Havn Life Science CSE: HAVN and Derrick Welsh Strategic Advisor to Revive Therapeutics CSE: RVV joined us talk about their recent psychedelic partnership agreement that both companies have entered into.

Based on the partnership the two companies have signed an agreement for supply of psychedelic compounds and usage to be used for ongoing research.

Revive Therapeutics intends to research both synthetic and natural derived psilocybin with the University of Wisconsin Madison. Natural derived psilocybin’s in the oral thin film technology is a leading trend within the psychedelic industry.

Related: Revive Therapeutics: Building A Diversified Asset Portfolio Across Multiple Sectors

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More